WHITTIER TRUST CO - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 121 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2023. The put-call ratio across all filers is 0.98 and the average weighting 0.3%.

Quarter-by-quarter ownership
WHITTIER TRUST CO ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q3 2023$2,494
-16.6%
2890.0%0.00%
Q2 2023$2,991
-4.6%
2890.0%0.00%
Q1 2023$3,135
-3.3%
2890.0%0.00%
Q4 2022$3,242
+8.1%
2890.0%0.00%
Q3 2022$3,0000.0%2890.0%0.00%
Q2 2022$3,0000.0%2890.0%0.00%
Q1 2022$3,0000.0%2890.0%0.00%
Q4 2021$3,000
+50.0%
2890.0%0.00%
Q3 2021$2,000
-50.0%
2890.0%0.00%
Q2 2021$4,000
-33.3%
2890.0%0.00%
Q1 2021$6,000
+20.0%
2890.0%0.00%
Q4 2020$5,000
+25.0%
2890.0%0.00%
Q3 2020$4,000
-33.3%
2890.0%0.00%
Q2 2020$6,000
-14.3%
2890.0%0.00%
Q1 2020$7,0000.0%2890.0%0.00%
Q4 2019$7,000
+16.7%
2890.0%0.00%
Q3 2019$6,000
+20.0%
2890.0%0.00%
Q2 2019$5,000
-54.5%
289
-40.3%
0.00%
Q1 2019$11,000
-8.3%
4840.0%0.00%
Q4 2018$12,000
-25.0%
4840.0%0.00%
Q3 2018$16,000
+45.5%
4840.0%0.00%
Q2 2018$11,000
-8.3%
4840.0%0.00%
Q1 2018$12,0004840.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q2 2023
NameSharesValueWeighting ↓
Chescapmanager LLC 1,134,718$23,160,0002.47%
Baupost Group 8,735,168$178,285,0001.42%
Orbimed Advisors 6,219,110$126,932,0001.19%
CM Management, LLC 50,000$1,021,0000.76%
Tekla Capital Management LLC 456,296$9,313,0000.32%
Rock Springs Capital Management LP 682,600$13,932,0000.30%
Virtus ETF Advisers LLC 32,871$671,0000.28%
Cormorant Asset Management, LP 550,000$11,226,0000.25%
DAFNA Capital Management LLC 41,165$840,0000.20%
PEREGRINE CAPITAL MANAGEMENT LLC 484,206$9,883,0000.18%
View complete list of THERAVANCE BIOPHARMA INC shareholders